<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mehta, Shamir</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results from CURRENT-OASIS 7</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">The Clopidogrel optimal loading dose Usage to Reduce Recurrent Events-Organization to Assess Strategies in Ischemic Syndromes [CURRENT-OASIS 7] trial was a 2×2 factorial, open-label, randomized trial to determine optimal clopidogrel and aspirin dosing in subjects with acute coronary syndrome within 24 hours of ischemic symptoms. The primary outcome was a composite of cardiovascular death, myocardial infarction, or stroke to Day 30.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>